Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Study Identifier:

17-AVP-786-305

ClinicalTrials.gov Identifier:

NCT03393520

EudraCT Identifier:

2017-001339-38

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Study Complete

Subscribe to Updates

Study Details

Medical Condition

Dementia/Alzheimer

Study Drug

Drug: Placebo
Drug: AVP-786

Date

Oct 2017 - Nov 2023

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 50 - 90 Years

Requirements Information

Protocol Summary

This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in participants with dementia of the Alzheimer's type.

Study Locations

Location

Status

Location

MD First Research #767

Chandler, Arizona, United States, 85286

Status

N/A

Location

Liv Generations of Agritopia / CCT #573

Gilbert, Arizona, United States, 85296

Status

N/A

Location

Liv Generations of Ahwatukee / CCT #784

Phoenix, Arizona, United States, 85048

Status

N/A

Location

Perseverance Research Center

Scottsdale, Arizona, United States, 85254

Status

N/A

Location

Medical Advancement Center of Arizona #820

Tempe, Arizona, United States, 85283

Status

N/A

Location

Clinical Trials Inc.

Little Rock, Arkansas, United States, 72205

Status

N/A